Request a Kinpeygo Visit

Request a visit

Request a Kinpeygo visit

Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with urine protein-to-creatinine ratio (UPCR) ≥ 1.5g/gram.

Prescribing Information can be found here.

Please leave your details below if you would like more information about Kinpeygo. Should you have any trouble completing this form please email us at HCPsupport@thorntonross.com

Required fields are marked with an asterisk *

What kind of visit would you like?

A visit from our Medical Science Liaison TeamA visit from our Healthcare Partnership Manager Team

What would you like to discuss?

Nefigan trial Patients at high risk of progression with a UPCR >1.5g/gram Medical enquiries Detailed clinical data Disease area discussions Something else

Your details

Name

NHS Email* / Phone number

Professional Code

Role*

Hospital/Practice Details*

NHS Work Address*

Please tick to confirm

I am an NHS UK healthcare professional

Let’s stay connected!

Want to be the first to hear about the products, services and educational resources we offer, including invitations to webinars and events.

Tick here to receive emails from STADA, Thornton & Ross.

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about how we process your data, please visit our website.

We use Mailchimp as our marketing platform. By clicking on the box to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp’s privacy practices here.

Should you have any trouble completing this form please email us at HCPsupport@thorntonross.com

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.

UK-KINPE-56(1) | April 2024